Relapsed Or Refractory Acute Myeloid Leukemia Aml clinical trials

Explore recruiting relapsed or refractory acute myeloid leukemia aml clinical trials.

Recruiting relapsed or refractory acute myeloid leukemia aml studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Acute Myeloid Leukemia Aml trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

Spain, Hungary, Czechia, France, Italy, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Poland, Germany, Sweden, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Spain, Italy, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Or Refractory Acute Myeloid Leukemia Aml trials by city

Relapsed Or Refractory Acute Myeloid Leukemia Aml in Toronto Relapsed Or Refractory Acute Myeloid Leukemia Aml in Vancouver Relapsed Or Refractory Acute Myeloid Leukemia Aml in Montreal Relapsed Or Refractory Acute Myeloid Leukemia Aml in Calgary Relapsed Or Refractory Acute Myeloid Leukemia Aml in Edmonton Relapsed Or Refractory Acute Myeloid Leukemia Aml in Ottawa Relapsed Or Refractory Acute Myeloid Leukemia Aml in Winnipeg Relapsed Or Refractory Acute Myeloid Leukemia Aml in Quebec City Relapsed Or Refractory Acute Myeloid Leukemia Aml in Hamilton Relapsed Or Refractory Acute Myeloid Leukemia Aml in Kitchener Relapsed Or Refractory Acute Myeloid Leukemia Aml in London Relapsed Or Refractory Acute Myeloid Leukemia Aml in Halifax Relapsed Or Refractory Acute Myeloid Leukemia Aml in New York Relapsed Or Refractory Acute Myeloid Leukemia Aml in Los Angeles Relapsed Or Refractory Acute Myeloid Leukemia Aml in Chicago Relapsed Or Refractory Acute Myeloid Leukemia Aml in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease